Diagnosis and management of heart failure in COPD

European Respiratory Monograph

Volumn 59, Issue , 2013, Pages 50-63

  Rutten, Frans H ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

COPD; Diagnosis; Heart failure; Management; Prognosis; Treatment

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; C REACTIVE PROTEIN; CHOLINERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; DIGITALIS GLYCOSIDE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; INTERLEUKIN 8; IRBESARTAN; METOPROLOL SUCCINATE; NATRIURETIC FACTOR; NEBIVOLOL; SPIRONOLACTONE; TUMOR NECROSIS FACTOR ALPHA;

AEROBIC EXERCISE; ARTICLE; CACHEXIA; CARDIAC RESYNCHRONIZATION THERAPY; CENTRAL VENOUS PRESSURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORONARY ARTERY DISEASE; DEFIBRILLATOR; DIASTOLIC DYSFUNCTION; DISEASE COURSE; DYSPNEA; ECHOCARDIOGRAPHY; FATIGUE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEART ATRIUM ENLARGEMENT; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTENSION; HYPOXEMIA; ISCHEMIC HEART DISEASE; LUNG FUNCTION TEST; LUNG VASOCONSTRICTION; MORBIDITY; MORTALITY; MUSCLE ATROPHY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; POSITIVE END EXPIRATORY PRESSURE; PROGNOSIS; RECURRENT DISEASE; SMOKING; SODIUM RETENTION; SWELLING; WATER RETENTION;

EID: 84874865454     PISSN: 1025448X     EISSN: 20756674     Source Type: Book Series    
DOI: 10.1183/1025448x.10011412     Document Type: Article

References (81)

1. Pedersen F, Mehlsen J, Raymond I, et al. Evaluation of dyspnoea in a sample of elderly subjects recruited from general practice. Int J Clin Pract 2007; 61: 1481-1491.
2. Mulrow CD, Lucey CR, Farnett LE. Discriminating causes of dyspnea through clinical examination. J Gen Intern Med 1993; 8: 383-392.
3. Fabbri LM, Luppi F, Beghé B, et al. Complex chronic comorbidities of COPD. Eur Respir J 2008; 31: 204-212.
4. Ebi K, Hawthorne VM, Rose G, et al. Breathlessness, chronic bronchitis and reduced pulmonary function as predictors of cardiovascular disease mortality among men in England, Scotland and the United States. Int J Epidemiol 1989; 18: 84-88.
5. Hole DJ, Watt GC, Davey S, et al. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. Br Med J 1996; 313: 711-715.
6. Berry CE, Wise RA. Mortality in COPD: causes, risk factors, and prevention. COPD 2010; 7: 375-382.
7. Sin DD, Anthonisen NR, Soriano JB, et al. Mortality in COPD: role of comorbidities. Eur Respir J 2006; 28: 1245-1257.
8. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003; 107: 1514-1519.
9. Rutten FH, Cramer MJ, Grobbee DE, et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J 2005; 26: 1887-1894.
10. Kachel R. Left ventricular function in chronic obstructive pulmonary disease. Chest 1978; 74: 286-290.
11. Rutten FH, Cramer MJM, Lammers JWJ, et al. Heart failure and chronic obstructive pulmonary disease: an ignored combination? Eur J Heart Fail 2006; 8: 706-711.
12. McCullough PA, Hollander JE, Nowak RM, et al. Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type natriuretic peptide in the emergency department. Acad Emerg Med 2003; 10: 198-204.
13. Hawkins NM, Petrie MC, Jhund PS, et al. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail 2009; 11: 130-139.
14. Hawkins NM, Petrie MC, Macdonald MR, et al. Heart failure and chronic obstructive pulmonary disease. The quandary of b-blockers and b-agonists. J Am Coll Cardiol 2011; 57: 2127-2138.
15. Mentz RJ, Fiuzat M, Kraft M, et al. Bronchodilators in heart failure patients with COPD: is it time for a clinical trial? J Card Fail 2012; 18: 413-422.
16. Au DH, Udris EM, Fan VS, et al. Risk of mortality and heart failure exacerbations associated with inhaled badrenoreceptor agonists among patients with known left ventricular dysfunction. Chest 2003; 123: 1964-1969.
17. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J 2012; 33: 1787-1847.
18. Global Strategy for the Diagnosis, Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2011. www.goldcopd.org Date last accessed: September 4, 2012.
19. Naeije R. Pulmonary hypertension and right heart failure in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 20-22.
20. Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J 2012; 33: 1750-1757.
21. van Jaarsveld CH, Ranchor AV, Kempen GI, et al. Epidemiology of heart failure in a community-based study of subjects aged o57 years: incidence and long-term survival. Eur J Heart Fail 2006; 8: 23-30.
22. Steinberg BA, Zhao X, Heidenreich PA, et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation 2012; 126: 65-75.
23. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J 2011; 32: 670-679.
24. Agmon Y, Khandheria BK, Meissner I, et al. C-reactive protein and atherosclerosis of the thoracic aorta: a population-based transesophageal echocardiographic study. Arch Intern Med 2004; 164: 1781-1787.
25. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol 2004; 43: 1731-1737.
26. Ross R. Atherosclerosis an inflammatory disease. N Engl J Med 1999; 340: 115-126.
27. Simanonok JP. Non-ischemic hypoxia of the arterial wall is a primary cause of atherosclerosis. Med Hypotheses 1996; 46: 155-161.
28. Vasan RS, Sullivan LM, Roubenoff R, et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 2003; 107: 1486-1491.
29. Murray DR, Freeman GL. Proinflammatory cytokines: predictors of a failing heart? Circulation 2003; 107: 1460-1462.
30. Assayag P, Benamer H, Aubry P, et al. Alteration of the alveolar-capillary membrane diffusing capacity in chronic left heart disease. Am J Cardiol 1998; 82: 459-464.
31. West JB, Mathieu C. Stress failure of pulmonary capillaries: role in lung and heart disease. Lancet 1992; 340: 762-767.
32. Gueder G, Rutten FH, Brenner S, et al. The impact of heart failure on the classification of COPD severity. J Card Fail 2012; 18: 637-644.
33. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet 1994; 344: 793-795.
34. Agustí A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 2012; 7: e37483.
35. Oudijk E-JD, Lammers J-WJ, Koenderman L. Systemic inflammation in chronic obstructive pulmonary disease. Eur Respir J 2003; 22: Suppl. 46, 5s-13s.
36. MacNee W. Pathogenesis of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 258-266.
37. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695.
38. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009; 33: 1165-1185.
39. Lange P, Mogelvang R, Marott JL, et al. Cardiovascular morbidity in COPD: a study of the general population. COPD 2010; 7: 5-10.
40. Klinger JR, Hill NS. Right ventricular dysfunction in chronic obstructive pulmonary disease. Evaluation and management. Chest 1991; 99: 715-723.
41. Burghuber O, Bergmann H, Silberbauer K, et al. Right ventricular performance in chronic air flow obstruction. Respiration 1984; 45: 124-130.
42. Morrison DA, Adcock K, Collins CM, et al. Right ventricular dysfunction and the exercise limitation of chronic obstructive pulmonary disease. J Am Coll Cardiol 1987; 9: 1219-1229.
43. Andreas S, Anker SD, Scanlon PD, et al. Neurohormonal activation as a link to systemic manifestations of chronic obstructive pulmonary disease. Chest 2005; 128: 3618-3624.
44. Forth R, Montgomery H. ACE in COPD: a therapeutic target? Thorax 2003; 58: 556-558.
45. Mancini GB, Khalil N. Angiotensin II type 1 receptor blocker inhibits pulmonary injury. Clin Invest Med 2005; 28: 118-126.
46. Aronow WS. Treatment of heart failure in older persons. Dilemmas with coexisting conditions: diabetes mellitus, chronic obstructive pulmonary disease, and arthritis. Congest Heart Fail 2003; 9: 142-147.
47. Guazzi M. Alveolar-capillary membrane dysfunction in heart failure: evidence of a pathophysiologic role. Chest 2003; 124: 1090-1102.
48. 123I-metaiodobenzylguanidine imaging in patients with COPD. Chest 1999; 116: 1575-1581.
49. Jackson G, Gibbs CR, Davies MK, et al. ABC of heart failure. Pathophysiology. Br Med J 2000; 320: 167-170.
50. Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation 2005; 111: 2837-2849.
51. Gosker HR, Lencer NH, Franssen FM, et al. Striking similarities in systemic factors contributing to decreased exercise capacity in patients with severe chronic heart failure or COPD. Chest 2003; 123: 1416-1424.
52. Schols AM. Nutritional and metabolic modulation in chronic obstructive pulmonary disease management. Eur Respir J 2003; 22: Suppl. 46, 81s-86s.
53. Rutten FH, Moons KCM, Cramer MJM, et al. Recognising heart failure in elderly patients with stable chronic obstructive pulmonary disease in primary care: cross sectional diagnostic study. Br Med J 2005; 331: 1379.
54. Boudestein LC, Rutten FH, Cramer MJM, et al. The impact of concurrent heart failure on prognosis in patients with chronic obstructive pulmonary disease. Eur J Heart Failure 2009; 11: 1182-1188.
55. Rusinaru D, Saadi I, Godard S, et al. Impact of chronic obstructive pulmonary disease on long-term outcome of patients hospitalized for heart failure. Am J Cardiol 2008; 101: 353-358.
56. Kwon BJ, Kim DB, Jang SW, et al. Prognosis of heart failure patients with reduced and preserved ejection fraction and coexistent chronic obstructive pulmonary disease. Eur J Heart Fail 2010; 12: 1339-1344.
57. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 2248-2261.
58. Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 1231-1239.
59. Fukata H, Sane DC, Brucks S, et al. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 2005; 112: 357-363.
60. Jabbour A, Macdonald PS, Keogh AM, et al. Differences between beta-blockers in patients with chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol 2010; 55: 1780-1787.
61. Hawkins NM, Wang D, Petrie MC, et al. Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. Eur J Heart Fail 2010; 12: 557-565.
62. Lin R, Peng H, Nguyen LP, et al. Changes in b2-adrenoceptor and other signaling proteins produced by chronic administration of "b-blockers" in a murine asthma model. Pulm Pharmacol Ther 2008; 21: 115-124.
63. Nguyen LP, Omoluabi O, Parra S, et al. Chronic exposure to b-blockers attenuates inflammation and mucin content in a murine asthma model. Am J Respir Cell Mol Biol 2008; 38: 256-262.
64. Rutten FH, Zuithoff NPA, Hak E, et al. β-blockers may reduce mortality and risk of exacerbations of patients with chronic obstructive pulmonary disease. Arch Intern Med 2010; 170: 880-887.
65. Short PM, Lipworth SI, Elder DH, et al. Effect of b-blockers in treatment of chronic obstructive pulmonary disease. Br Med J 2011; 342: d2549.
66. Etminan M, Jafari S, Carleton B, et al. β-blocker use and COPD mortality: a systematic review and meta-analysis. BMC Pulm Med 2012; 12: 48.
67. Andreas S, Herrmann-Lingen C, Raupach T, et al. Angiotensin II blockers in obstructive pulmonary disease: a randomised controlled trial. Eur Respir J 2006; 27: 972-979.
68. Mancini GB, Etminan M, Zhang B, et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006; 47: 2554-2560.
69. Mortensen EM, Copeland LA, Pugh MJV, et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Resp Res 2009; 10: 45.
70. Agostoni P, Magini A, Andreini D, et al. Spironolactone improves lung diffusion in chronic heart failure. Eur Heart J 2005; 26: 159-164.
71. Zhang J, Zhao G, Yu X, et al. Intravenous diuretic and vasodilator therapy reduce plasma brain natriuretic peptide levels in acute exacerbation of chronic obstructive pulmonary disease. Respirology 2012; 17: 715-720.
72. Walsh GM. Defective apoptotic cell clearance in asthma and COPD: a new drug target for statins? Trends Pharmacol Sci 2008; 29: 6-11.
73. Morimoto K, Janssen WJ, Fessler MB, et al. Lovastatin enhances clearance of apoptotic cells (efferocytosis) with implications for chronic obstructive pulmonary disease. J Immunol 2006; 176: 7657-7665.
74. Lee JH, Lee DS, Kim EK, et al. Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med 2005; 172: 987-993.
75. Keddissi JI, Yuonis WG, Chbeir EA, et al. The use of statins and lung function in current and former smokers. Chest 2007; 132: 1764-1771.
76. Alexeeff SE, Litonjua AA, Sparrow D, et al. Statin use reduces decline in lung function: VA Normative Ageing Study. Am J Respir Crit Care Med 2007; 176: 742-747.
77. Janda S, Park K, FitzGerald JM, et al. Statins in COPD. A systematic review. Chest 2009; 136: 734-743.
78. Calverly PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone proprionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789.
79. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-1554.
80. Chong J, Karner C, Poole P. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 9: CD009157.
81. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium I chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 217-224.